Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol with Immune Checkpoint Inhibitors in Urothelial Carcinoma
NCT04848519Phase 2Active, not recruiting
- Sponsor
- Emory University
- Start
- May 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of propranolol in urothelial carcinoma (UC), sponsored by Emory University. Started May 2021; status: active, not recruiting.
02
Drugs
propranolol
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04848519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848519.